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Communicated by Mireille Claustres 
Autosomal recessive spastic paraplegia with thinning of corpus callosum (ARHSP-TCC) 
is a complex form of HSP initially described in Japan but subsequently reported to have 
a worldwide distribution with a particular high frequency in multiple families from the 
Mediterranean basin. We recently showed that ARHSP-TCC is commonly associated 
with mutations in SPG11/KIAA1840 on chromosome 15q. We have now screened a 
collection of new patients mainly originating from Italy and Brazil, in order to further 
ascertain the spectrum of mutations in SPG11, enlarge the ethnic origin of SPG11 
patients, determine the relative frequency at the level of single Countries (i.e., Italy), and 
establish whether there is one or more common mutation. In 25 index cases we identified 
32 mutations; 22 are novel, including 9 nonsense, 3 small deletions, 4 insertions, 1 in/del, 
1 small duplication, 1 missense, 2 splice-site, and for the first time a large genomic 
rearrangement. This brings the total number of SPG11 mutated patients in the 
SPATAX collection to 111 cases in 44 families and in 17 isolated cases, from 16 
Countries, all assessed using homogeneous clinical criteria. While expanding the 
spectrum of mutations in SPG11, this larger series also corroborated the notion that 
even within apparently homogeneous population a molecular diagnosis cannot be 
achieved without full gene sequencing. © 2008 Wiley-Liss, Inc. 
KEY WORDS: ARHSP; TCC; SPG11; mutation screening. 
INTRODUCTION 
Hereditary spastic paraplegias (HSPs), also known as Strümpell-Lorrain disease, are a heterogeneous group 
of inherited disorders in which the main clinical feature is progressive spasticity in the lower limbs due to 
pyramidal tract dysfunction (Harding 1983). Brisk tendon reflexes with bilateral Babinski sign, muscle 
weakness and urinary urgency are also present at clinical examination and are likely the result of a ‘dying 
back’ degeneration of the corticospinal tracts. Scholastically, HSPs are classified as pure or complex 
depending on whether spasticity in the lower limbs occurs in isolation or it is associated with other 
neurological and extraneurological signs (Harding 1983; Tallaksen et al. 2001; Depienne et al. 2007). 
However, an ever widening clinical spectrum, the recognition of subtle differences between apparently 
stereotypical neurological disorders, and the large underlying genetic heterogeneity call for a more locus-
driven classification in HSP (Fink 2006; Stevanin et al. 2008b).  
Autosomal recessive spastic paraplegia with thinning of the corpus callosum (ARHSP-TCC; MIM# 
604360) is a frequent and complex form of HSP initially described in Japan (Nakamura et al. 1995). Since the 
initial reports linking Mediterranean and Asian ARHSP-TCC families to the SPG11 locus on chromosome 15q 
(Martinez-Murillo et al. 1999; Shibasaki et al. 2000), several groups, including our teams, proved that this 
phenotype has a worldwide distribution (Casali et al. 2004; Lossos et al. 2006; Olmez et al. 2006; Winner et 
al. 2006; França et al. 2007; Stevanin et al. 2007, 2008a) and that it is particularly prevalent in the 
Mediterranean basin (Casali et al. 2004; Stevanin et al. 2006). More recently, we showed that ARHSP-TCC at 
this locus is associated with mutations in SPG11/KIAA1840 (MIM# 610844), a gene with an open reading 
frame of 7,787 nucleotides that comprises 40 exons and which spans a genomic region of approximately 100 
Kb (Stevanin et al. 2007). SPG11 is predicted to encode a 2,443 amino-acid-long protein, which has no 
homology with known proteins although a high degree of conservation is present across vertebrates. Its 
involvement in ARHSP-TCC was subsequently confirmed by other groups (Del Bo et al. 2007; Hehr et al. 
2007; Paisan-Ruiz et al. 2008; Lee et al. 2008; Zhang et al. 2008). 
We have recently reported the clinical and molecular genetic features of the largest group of SPG11 
patients, mainly coming from Western Europe and North-Africa, collected within SPATAX, an European and 
Mediterranean network for spinocerebellar degenerations (Stevanin et al. 2008a). We have now screened a 
collection of new patients referred to a single centre, and mainly originating from Italy and Brazil, in order to 
further ascertain the spectrum of mutations in SPG11, enlarge the ethnic origin of SPG11 patients, determine 
the relative frequency at the level of single Countries (i.e., Italy), and establish whether there is one or more 
common mutation. We identified 22 new mutations and analyzed the associated phenotypes. 
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METHODS  
Patients 
Thirty-one kindred (57 patients) with an autosomal recessive inheritance and 20 isolated cases with no 
apparent family history of the disease were selected in our shared databases and were classified in four 
diagnostic categories: i) spastic paraplegia with mental retardation (MR) or cognitive impairment and thinning 
of the corpus callosum (TCC) demonstrated by brain MRI in at least one affected member (36 in 20 families 
and 8 isolated cases), ii) spastic paraplegia with TCC in at least one affected member (7 in 4 families and 10 
isolated cases), iii) spastic paraplegia with cognitive impairment but without TCC in all affected members (7 
in 4 families and 2 isolated cases), iv) “apparently” pure spastic paraplegia without TCC at MRI (7 cases in 3 
families).  
Clinical and paraclinical evaluations followed a protocol established by the SPATAX network 
(coordinator: Dr A. Durr) that included: full medical history and physical examination, estimation of the age 
and the symptoms at onset in the patient, disease duration and severity according to the Spastic Paraplegia 
Rating scale (Schule et al. 2006), presence/absence of additional neurological symptoms/signs, 
electromyographic (EMG) and nerve conduction velocity (NCV) studies, and brain and spinal cord MRI 
whenever possible. Neuropsychological evaluations were performed in the vast majority of cases by 
measuring their IQ, the Mini Mental State Evaluation (MMSE), and the Wechsler Memory Scale (Wechsler 
1987). According to the DSM-IV criteria (2000), mental retardation was considered when the patient had an 
IQ< 70 before the age of 18 years.  
Having received the patients’ (or their parents’) written informed consent and the authorization of our local 
Ethical Committees, we purified genomic DNA from peripheral blood samples for subsequent genetic 
analyses. In all the patients, we had previously ruled out other causes of acquired spastic paraplegia such as 
multiple sclerosis, adrenoleukodystrophy, and mitochondrial diseases, as described (Casali et al. 2004). 
Fifteen of the 31 families were Italian, eight were Brazilian, two were Turkish and one each was from 
Malta, Germany (with Turkish origin), Austria, The Netherlands, Montenegro, and Slovenia. Seventeen 
families were non-consanguineous and 14 consanguineous. Most of the 20 isolated patients were Italian 
(n=14), three Brazilian whereas the remaining originated from other European countries. In sporadic cases, 
mutations or rearrangements in the SPG4 gene and mutations in the SPG7 and SPG21 genes had also been 
excluded (data not shown). 
Mutation detection 
The coding sequence and splice site boundaries of the 40 exons of the SPG11/KIAA1840 gene (GenBank 
reference sequence NM_025137.3) were amplified by PCR and sequenced on both strands using the Big Dye 
chemistry (Applied Biosystems, Foster City, CA) as previously described (Stevanin et al. 2007). In non 
mutated cases, in addition to the coding sequence, 1166 bp upstream the first ATG and 425 bp downstream the 
last termination codon of the SPG11 gene were amplified with a classical protocol and sequenced using four 
primers pairs (Supp. Table S1). The sequence products were run on an automated ABI 3730 sequencer and the 
results were analyzed with SeqScape 2.5 software (Applied Biosystems). Alternatively, PCR products 
generated using primers and PCR conditions indicated in Supp. Table S2 were processed for denaturing High 
Performance Liquid Chromatography (d-HPLC). To this end, the untreated PCR products (5–15µl) from the 
patients and a control DNA — previously deemed free of sequence variants — were mixed, denatured at 94°C 
for 5 minutes and renaturated overnight at room temperature to allow the formation of heteroduplex prior to d-
HPLC analysis. Samples were then analyzed using the Transgenomic WAVE DHPLC system (Transgenomic 
Inc, Omaha, NE) and results were interpreted essentially as reported (Patrono et al. 2005).  
Segregation of mutations detected in this study was verified by direct sequencing or d-HPLC, or both in all 
available family members whenever possible. In addition, the relative frequencies of missense variants were 
determined on unrelated healthy controls (100 Italians and 50 European Caucasians), for a total of 300 
chromosomes, by d-HPLC, ad hoc designed PCR-restriction fragment length polymorphisms (data not shown) 
or direct sequencing. Synonymous, missense and splice site variations were systematically evaluated for 
modifications of exonic splicing enhancers (www.rulai.cshl.edu/cgi-bin/tools/ESE/esefinder.cgi) or consensus 
splicing sequences  in order to determine the splice site score 
E503         Further Mutations in SPG11  
(rulai.cshl.edu/new_alt_exon_db2/HTML/score.html and www.fruitfly.org/seq_tools/splice.html). Multiple 
alignments with spatacsin orthologs were performed using ClustalW (www.ebi.ac.uk/clustalw/) to evaluate the 
degree of conservation of missense variants. 
Nomenclature of mutations and variants followed the guidelines of the Human Genome Variation Society 
(http://www.hgvs.org/mutnomen) and referred to the cDNA sequence (GenBank reference sequence version 
NM_025137.3) with the A of the translation initiation codon as +1. 
Haplotyping 
In order to identify possible shared haplotypes between families carrying the same mutations, we 
genotyped the SPG11 flanking microsatellites D15S781, D15S537, D15S516, and D15S659. We also used two 
new flanking markers, one of which lies in SPG11 (primers listed in Supp. Table S1). PCR-amplified 
fragments were pooled with GeneScan500Liz marker, sized on an ABI 3730 automated sequencer and 
analyzed with GeneMapper 4 software (Applied Biosystems), according to the manufacturer’s 
recommendations. Haplotypes were manually reconstructed considering the minimal number of 
recombinations.  
Other methods 
Cultured skin fibroblast polyA+ RNA was purified and reversely transcribed using the 1st Strand cDNA 
Synthesis Kit (Roche, Hamburg, Germany) according to the manufacturer’s random primer protocol, and the 
consequences of the exon 24 c.4046T>A/p.F1349I mutation on splicing in patient F33[COL] was examined by 
RT-PCR using primers designed in exons 16 and 30. 
To determine the segregation of the large-scale rearrangement in family F-NL02 we PCR-amplified a 
genomic fragment using oligonucleotide primers Spg11-30delF (5’-3’) AAT GTA TTG GGT TGC TTT CCT 
G and Spg11-35R (5’-3’) CCC TCC ATT TTC CCA AGA GT, High Fidelity Taq Polymerase (Roche 
Diagnostic, Milan, Italy) and PCR conditions consisting of 25 cycles of 15 s at 94°C, 30 s at 57°C, and 8 min 
at 68°C with an increase of 5 s/cycle after the first 10 cycles. 
RESULTS 
SPG11 mutation screening 
SPG11 mutation screening has been undertaken in at least one index case in 31 families with a neurological 
picture highly resembling the clinical features of ARHSP-TCC (Shibasaki et al. 2000; Casali et al. 2004; 
Lossos et al. 2006; Stevanin et al. 2006; Winner et al. 2006) and in whom linkage to chromosome 15q had not 
been established a priori. We also included in the study a subset of isolated cases (n=20). In a total of 25 of 
these patients (16 familial index cases and 9 sporadic), we detected 32 different sequence changes in the 
coding regions or consensus splice sites of the SPG11 gene; 22 of these are novel mutations whereas 10 have 
previously been reported (Table 1).  
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Table 1. List of SPG11 mutations identified in this study (GenBank reference sequence NM_025137.3).  
Mutation Type Nucleotide/Amino acid position Exon 
Homo- or 
heterozygous 
state 
Family (n index 
cases)  
Origin Reference 
Nonsense c.268G>T/p.E90X   2 Heterozygous F-BRA12175 (1) BR This study 
  c.1679C>G/p.S560X  8 Heterozygous F16[SB] (1)  IT This study 
  c.1951C>T/p.R651X  10 Heterozygous MP; F28[VAC] (3)  IT This study 
  c.2697G>A/p.W899X  15 Homozygous F10; TK-SH  (4)  TR This study 
  c.5470C>T/p.R1824X 30 Heterozygous F8  (1)  DE This study 
  c.5870C>G/p.S1957X  31 Heterozygous F16[SB]  (1)  IT This study 
  c.5970C>G/p.Y1990X 31 Homozygous FA  (2)  IT  This study 
  c.6091C>T/p.R2031X  32 Homozygous F1  (3)  TR/DE  Lee et al. 2008 
  c.6100C>T/p.R2034X  32 Homozygous F-BRA21325  (2)  BR Stevanin et al. 2007 
  c.6856C>T/p.R2286X    38 Heterozygous F14[CAL]  (1)  IT This study 
  c.7023C>A/p.Y2341X 39 Homozygous F-BRA21215  (2)  BR This study 
Insertion/deletion c.408_428del21/p.E136_I142del 2 Heterozygous F35[TER] (1)  IT This study 
  c.529_533del5/p.I177_F178del>S177fsX180 3 Heterozygous 
F17[BRA];  
F-BRA12175  (2)  
BR  Stevanin et al. 2007 
  c.733_734del2/p.M245VfsX247   4 
Hetero- and 
Homozygous 
F-BRA12162;  
F-BRA19070;  
F35[TER] (5) 
BR; IT Stevanin et al. 2007 
  c.1203delA/p.K401fsX415  6 Heterozygous F17[SP]; FB (3)  IT  Stevanin et al. 2007 
  c.1697_1712del16insTACTCCCAT/p.D566VfsX595 8 Heterozygous DKD  (2)  IT This study 
  c.2355_2356del2/p.K785SfsX796   13 Homozygous F34[GARG] (1)  IT This study 
  c.2716delC/p.Q906SfsX920   15 Homozygous F9 (2)  BR This study 
  c.2849_2850insT/p.L950FfsX953  16 Heterozygous MP (2) IT This study 
  c.3075_3076insA/p.E1026RfsX1029 17 Heterozygous F8; F33[COL] (2) DE; IT Hehr et al. 2007 
  c.3664_3665insT/p.K1222IfsX1236 21 Heterozygous F17[SP] (1) IT This study 
  c.3741_3742insA/p.P1248TfsX1264  22 Heterozygous F17[BRA] (1) BR This study 
  c.4307_4308del2/p.Q1436RfsX1442   25 Heterozygous F16[BRA] (1)  BR  Stevanin et al. 2008a 
  c.5255delT/p.F1752SfsX1837  30 Heterozygous SP (2)  IT  Hehr et al. 2007  
  c.5987_5990dupCTCT/p.C1996fsX1999  31 Heterozygous DKD (2) IT  This study 
  c.5986_5987insT/p.C1996LfsX1999 31 Heterozygous SP (2)  IT Stevanin et al. 2008a 
  c.5992insT/p.Y1998fsX1999  31 Heterozygous FB (2) IT This study 
  c.5898+5493_6509-491del/p.T1966fsX1968 31-34 Homozygous F-NL02 (1)  NL This study 
Splice-site c.2444G>T/p.R815M, r.? 13 Heterozygous F28[VAC] (1) IT This study 
  c.2444+1G>C, r.? Intron 13 Heterozygous F16[BRA] (1)  BR This study 
   c.2833A>G/p.R945GfsX950, r.2834_2835ins2834+1_2834+65 15 Heterozygous F14[CAL]  (1)  IT Stevanin et al. 2008a 
Missense c.4046T>A/p.F1349I 24 Heterozygous F33[COL] (1) IT This study 
 
New mutations are indicated in bold. Origin of patients adopts the ISO indication for Country code.
 E505          Further Mutations in SPG11  
Figure 1 shows a sample of the mutations detected in this study. In 24 cases, including 9 sporadic patients, the 
segregation was verified within the family throughout the analysis of 60 additional samples, of whom 15 were 
affected and 45 healthy relatives. Overall, 40 patients showed to have SPG11 mutations on both alleles. 
 
 
 
Figure 1. A sample of the new SPG11 mutations identified in this study. A selection of the electropherograms flanking novel 
mutations in the SPG11 gene is shown. Their segregation in the patients’ family is also indicated. The novel mutations are 
indicated by arrows. Square symbols are men, the circles are women. The filled symbols are affected individuals. Stars indicate 
sampled subjects. M = mutation; + = wild type. 
 
The index cases in 12 kindred presented with a homozygous mutation, whereas two heterozygous variants were 
detected in four families. Not too surprisingly, we only found compound heterozygosity in the 9 remaining isolated 
cases, all non-consanguineous. The majority of the mutations (Table 1) were predicted to be pathogenic because 
they lead to an early stop codon or frameshift, producing a premature termination of translation, and included 
nonsense mutations (n = 11), small deletions (= 8), small insertions (= 6), small duplication (= 1). It is of note that in 
one family (DKD) we detected a new micro-rearrangement (c.1697_1712del16insTACTCCCAT/p.D566VfsX595) 
at the compound heterozygous state. Also, we detected the first homozygous large-scale rearrangement sized about 9 
Kb (c.5898+5493_6509-491del) in a Dutch family (F-NL02) predictably resulting in premature protein truncation at 
residue 1968 (p.T1966fsX1968) (Figure 2). The mutation deleted the sequences of exons 31-34 and was flanked by 
a 42-bp repeat sequence (5’-ggtggctcacgcctgtaatcccagcactttgggaggccgagg -3’). Moreover, three changes 
(c.2444G>T; c.2444+1G>C; c.2833A>G) – which  were ruled out in 150 controls and expected to involve 
nucleotides predicted to alter the correct splicing of the SPG11 mRNA ― were detected on one allele in three 
families. In the Italian family F28[VAC] the c.2444G>T mutation affected the last nucleotide of exon 13, predicting 
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a missense change (p.R815M), but also altering the 5’-splicing donor site of intron 13 (splice score of +0.2 versus 
+3.7). In the Brazilian kindred F16[BRA], mutation c.2444+1G>C affected the first base of the splice donor site and 
likely led to abolition of splicing at this site (splice score of -7 versus +3.7). Although strongly predicted in silico, 
effects on splicing could not be experimentally tested in living cells. In addition, the c.2833A>G variation detected 
in the Italian family F14[CAL] affected the last nucleotide of exon 15, predicted a missense change (p.R945G) and 
caused the reduction of the splice score from +4.9, for the wild type, to +2.7. When this same mutation was detected 
in an ARHSP-TCC Israeli kindred (Stevanin et al. 2008a), analyses of mRNA from patients have shown alteration 
of SPG11 mRNA splicing with retention of 65-bp of intron 15 and subsequent early stop codon 
(r.2834+1_2834+65ins/ p.R945GfsX950). Interestingly, a missense mutation was detected in a single Italian patient 
F33[COL] who harbored the c.4046T>A/p.F1349I mutation in compound heterozygosity with the 
c.3076_3077insA/p.E1026RfsX1029. Residue F1349 is a well-conserved amino acid in other vertebrates and was 
not found mutated in 300 control chromosomes of European ancestry. When tested in cultured skin fibroblasts from 
the patient, the c.4046T>A/p.F1349I did not affect mRNA stability or correct splicing (not shown). 
 
 
Figure 2. A novel c.5898+5493_6509-491del large-scale rearrangement encompassing exons 31-34 of the SPG11 gene. Top 
panel. Polymerase Chain Reaction (PCR) detection of the novel c.5898+5493_6509-491del large-scale rearrangement in SPG11 
found in family F-NL02. C, control; P, patient F-NL02; MW, DNA 100-bp molecular marker size. Bottom panel. Using PCR 
conditions outlined in the text (see methods), a ~9.0 Kb fragment is amplified in a normal control (C) whereas a 720-bp fragment 
is detected in the propositus of kindred F-NL02 (P) as the result of the homozygous large scale deletion. Both the healthy parents 
(F, father and M, mother) and the brother (B) carried the heterozygous deletion. MW, DNA 1-Kb molecular size marker.
 
Molecular analyses identified families harboring the same mutation and sharing the same haplotype although they 
bear different surnames and formally deny relationships. As an example, we detected the homozygous c.2697G>A 
(p.W899X) in two presumably unrelated Turkish families (F10 and TK-SH) and the homozygous c.733_734del2 
(p.M245VfsX247) variant in two seemingly unrelated Brazilian kindred (F-BRA12162 and F-BRA19070) (see 
 E507          Further Mutations in SPG11  
Table 2). However, we cannot exclude the existence of a distant common ancestor. The c.733_734del2 mutation has 
already been reported in four families, two of which are shown in Table 2, in association with different haplotypes 
(Stevanin et al. 2007; Del Bo et al. 2007; Hehr et al. 2007; Stevanin et al. 2008a). Moreover, we found the 
c.1951C>T (p.R651X) in two apparently unrelated families who originated from the same geographical region in 
central Italy and shared partial common haplotype, although different from the previously reported patient from 
Romania (Stevanin et al. 2008a). We also observed mutations recurring in several ethnicities. As an example, we 
found the frequent homozygous c.6100C>T (p.R2034X), already detected in northern African families (Stevanin et 
al. 2007; Stevanin et al. 2008a; Boukhris et al. 2008a), in one Brazilian kindred with partially common haplotypes 
(see Table 2). Similarly, the c.529_533del5 (p.I177_F178del>S177fsX) mutation, already reported in three 
Portuguese families (Stevanin et al. 2007; Stevanin et al. 2008a), was also detected in an additional Brazilian family 
again segregating with a similar disease-bearing chromosome. 
Besides pathogenic changes in SPG11, we detected two reported homozygous SNPs (dbSNP: rs3759875 and 
rs3759873), two frequent heterozygous polymorphisms (p.F463S, and p.Y2341Y) (Stevanin et al. 2008a), and one 
new variant (p.K1273R); these variants were also detected in about 3% of normal alleles.  
No mutations in coding exons and flanking introns were detected in 15 familial index cases, and in 11 isolated 
patients. Sequencing of 1166 bp upstream the first ATG and 425 bp downstream the last termination codon did not 
reveal mutations, too. These cases were not informative enough to formally exclude the involvement of SPG11 
through microsatellite genotyping, however. 
Clinical characteristics of the new SPG11 patients  
Clinical information was available for all cases in which we could ascertain the presence of two mutant alleles. 
Table 3 reports clinical findings in the 40 individuals who proved to carry pathogenic variants on both alleles. 
Familial and sporadic cases did not present with distinguishable clinical profiles. Also, the phenotype of patients 
harboring the missense mutation was similar to that of the patients having variants predicting early protein 
truncation. The disease followed a broadly similar course and affected siblings tended to show the same pattern of 
symptom evolution and rate of disease progression. Age at onset of the disease ranged from 5 to 23 with a mean of 
14.0±4.1 years and it was mostly characterized by difficult walking (75%) with leg stiffness, gait abnormalities and 
in some cases frequent falls whereas learning disabilities were the presenting symptom in 13% of the cases. In the 
remaining cases, both deterioration of gait and cognitive delay occurred at the same time or their onset could not be 
recorded accurately. In a single patient (DKD-H83) the disease manifested initially with upper limbs tremor at age 
17 years but pyramidal tract signs and cognitive delay followed within two years. After a mean disease duration of 
7.9±5.5 years, all affected members of the families presented with a mild to severe spasticity of the legs with 
weakness in most. Deep tendon reflexes were brisk in the legs and, after less than 10 years, also in the arms. Most of 
the patients had mental impairment (87%) with objective evidence in 20 patients with IQ ranging from 53 to 69. 
Few cases initially showed a low-normal IQ but scored poorly at subsequent testing. 
The MRI scans were not recorded in three cases with disease duration of two, four and 12 years. However, their 
similarly affected sibs had shown typical neuroimaging features of TCC. Neuroradiological evidence of TCC was 
present in 34/37 (91.8%) patients with scans recorded whereas white matter hyperintensities were detected in 57%. 
Cortical or cerebellar atrophy, or both, were noted in seven patients (19%). Two familial cases only presented with 
moderate white matter signal abnormalities at the frontal horns of the lateral ventricles. Only one patient had a 
normal MRI, but after a disease duration of less than one year.  
Less frequent additional neurological findings consisted of cerebellar ataxia in 32% and extrapyramidal features 
in 16% of the cases (Table 3), usually in late stages of the disease. Signs of axonal neuropathy were detected in 
15/34 patients (44%). Few patients showed neurogenic changes resembling lower motor neuron involvement. A 
slow electroencephalogram was also recorded in two cases. A single patient showed reduced visual acuity at night 
but neither electroretinogram nor detailed fundoscopy were performed; another case carried a psychiatric diagnosis 
of bipolar disorder with psychosis and hallucinations. Concurrent Down syndrome was also observed in one case 
(Table 3). 
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Table 2. Haplotypes of six close markers segregating with the recurrent mutations in the SPG11 gene in this study and in previous reports.  
 
Family 
Origin 
F10 
Turkey 
TK-SH 
Turkey 
 Family 
Origin 
F-BRA12162 
Brazil 
F-BRA19070 
Brazil 
FSP117* 
France 
FSP870# 
Tunisia 
D15S781 185 185  D15S781 187 187 185 187 
D15S537 180 180  D15S537 160 160 172 180 
Chr15 :42720928^ 280 280  SPG11 exon 4 c.733_734del2 c.733_734de2 c.733_734del2 c.733_734del2 
SPG11 exon 15 c.2697G>A c.2697G>A  Chr15 :42720928^ 272 272 278/280 286 
Chr15 :42800751¤ 198 198  Chr15 :42800751¤ 198 198 196/198 196 
D15S516 195 195  D15S516 195 195 195 195 
D15S659 199 199  D15S659 175 179 179 195 
 
Family 
Origin 
F28[VAC] 
Italy 
MP 
Italy 
FSP683# 
Romania 
D15S781 185 185 187/191 
D15S537 172/176 172/176 164/184 
Chr15 :42720928^ 278/280 278/280 278/280 
SPG11 exon 10 c.1951C>G c.1951C>G c.1951C>G 
Chr15 :42800751¤ 198 198 194/198
D15S516 195 195 193/195
D15S659 199/179 195/183 199/179
 
 
Family 
Origin 
FSP732* 
Algeria 
FSP446* 
Morocco 
FSP881# 
Tunisia 
FSP221* 
Algeria 
FSP792# 
Morocco 
FS845# 
Morocco 
F-BRA21325 
Brazil 
FSP400# 
Algeria 
D15S781 185 185 185 185 185 185 185 185 
D15S537 176 180 180 176 176 176 176 180 
Chr15 :42720928^ 282 280 280 280 280 280 280 280 
SPG11 exon 32 c.6100C>T c.6100C>T c.6100C>T c.6100C>T c.6100C>T c.6100C>T c.6100C>T c.6100C>T 
Chr15 :42800751¤ 198 198 198 198 196 196 196 196 
D15S516 191 191 191 191 191 191 191 191 
D15S659 175 179 179 179 179 179 191 195 
 
 
Family 
Origin 
FSP831# 
Portugal 
FSP754* 
Portugal 
FSP386* 
Portugal 
F17[BRA] 
Brazil 
FSP386* 
Portugal 
D15S781 185 185 185 185 185 
D15S537 172 172 172 ND 172 
SPG11 exon 3 c.529_533del5 c.529_533del5 c.529_533del5 c.529_533del5 c.529_533del5 
Chr15 :42720928^ 286 286 286 282/286 286 
Chr15 :42800751¤ 196 196 196 196 194 
D15S516 195 195 195 195 193 
D15S659 203 203 195 195 195 
 
*Stevanin et al. 2007; Del Bo et al. 2007, #Stevanin et al. 2008a, ND= not done; ^ = Intragenic marker; ¤ = 3’ UTR marker. Conserved regions are highlighted in grey. 
Genotypes are indicated in base pairs. 
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Table 3. Clinical features of 40 patients with mutations in the SPG11 gene.  
 
M= male, F= female, ND= not done, UL= upper limbs, LL= lower limbs, IQ= intellectual quotient, MMSE= Mini Mental State Evaluation, ++= increased; += present; -= 
absent; PWM, periventricular white matter; TCC= thin corpus callosum. 
Patient ID code Origin (ISO cod) 
Age at 
examin
ation 
(years)/
sex 
Age at onset 
(years) 
Symptom at 
onset Severity 
LL 
spasticity/ 
weakness 
LL 
reflexes
UL 
reflexes 
Ext 
plantar 
Muscle 
wasting 
Mental Retardation/ 
Cognitive decline MRI EMG Other 
F-BRA12175  BR 12/F 7 Difficulties  at school Mild Mild/No + ++ MUTE - Delay 
TCC, 
PWM Normal  
F16[SB] IT 25 10 
Difficulties in 
concentration 
and walking 
Moderate 
Moderate 
spasticity, 
Walking 
difficulties 
++ +++ + + Mental deterioration TCC, PWM 
Neuropathic 
changes 
Slight tremor 
finger to nose 
F17[BRA] BR 17/F 15 Spasticity Mild Mild/No + +++ + - Retarded TCC, PWM Normal  
MP-1 IT 26/M 18 Spasticity Severe Severe/ Moderate Normal ++ ++ - 
Mental retardartion/ 
Progressive cognitive 
deterioration 
TCC, 
PWM, 
Cortical 
atrophy 
Axonal 
Neuropathy  
MP-2 IT 21/F 20 Spasticity Moderate Moderate/ Moderate ++ ++ ++ - Moderate 
TCC, 
PWM 
Axonal 
Neuropathy Urinary urgency 
F28[VAC] IT 18F 14 Feet deformities and stiff legs Moderate 
Moderate/ 
Mild - ++ + - No cognitive deficit 
TCC, 
PWM Normal Severe pes cavus 
F10-1 TK 12/M 10 Falls Severe Severe/ Moderate ++ ++ ++ + 
Mental retardation/ 
Progressive cognitive 
deterioration 
 
TCC, 
PWM, 
Cortical 
atrophy 
Axonal 
Neuropathy  
 
F10-2 
 
TK 16/M 14 Tremor Moderate Severe/ Moderate + ++ + - Cognitive delay ND ND Slow EEG 
TK-SH-1 TK 27 8 Deterioration  of gait 
Moderate, 
at 22 yrs still 
able to walk 
with crutches 
Moderate 
LLspasticity, 
Feet drop 
due to 
weakness 
of ant. tibial 
muscle 
++ +++ ++ + Some cognitive decline 
Mildly 
increased 
signal of 
periventri
cular and 
deep 
cerebral 
white 
matter, 
“Flames” 
at the 
frontal 
horns, 
Mild 
cerebral 
atrophy, 
TCC 
Axonal 
Neuropathy 
Dysartria, 
Decreased 
manual dexterity 
TK-SH-2 TK 22  10 
Deterioration 
 of gait 
Mostly 
wheelchair 
dependent 
Moderate 
LLspasticity, 
Feet drop 
due to 
weakness 
of  tibial muscle 
++ +++ Equivocal + Cognitive decline ibidem 
Axonal 
Neuropathy 
(mild) 
Down syndrome, 
Progressive 
serious dysarthria, 
Decreased 
manual dexterity 
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Patient ID code Origin (ISO cod) 
Age at 
examin
ation 
(years)/
sex 
Age at onset 
(years) 
Symptom at 
onset Severity 
LL 
spasticity/ 
weakness 
LL 
reflexes
UL 
reflexes 
Ext 
plantar 
Muscle 
wasting 
Mental Retardation/ 
Cognitive decline MRI EMG Other 
F8 DE 24/F 10 
Deterioration 
 in school 
performance 
(10yrs), Gait 
disturbance 
(14 yrs) 
Progressive 
deterioration, 
now severely 
disabled 
Standing 
with support,  
No walking 
+++ +++ + - 
Initial normal cognitive 
development, Mental 
deterioration starting 
at 10 yrs 
TCC, 
PWM, 
Cortical 
atrophy 
NC studies 
normal, 
EMG of ant. 
tibial muscle 
showed 
mild 
neurogenic 
changes at 
17 yrs 
Foot drop 
 
 
 
FA-1 
 
 
 
IT 17/F 15 Spasticity Mild Moderate/ No + +++ ++ - 
Mental retardation, 
Progressive cognitive 
deterioration 
TCC ND Visual problems at night 
 
FA-2 
 
IT 12/F 12 Delayed Mild Mild/No + ++ ++ - Delayed learning and memory Normal ND  
 
 
F1-1 
 
 
TK-DE 22/F 10 Walking difficulties 
Moderately 
impaired +++ ++ +++ + - 
Severe, she can 
hardly add 4 + 5 TCC ND  
 
F1-2 
 
TK-DE   24/M 15 Walking difficulties 
Now: can 
hardly walk +++ ++ +++ - - 
Now communication 
via language is hardly 
possible, but he can 
add  
4 + 5 
TCC 
Nerve 
conduct. 
study 
compatible 
with mild 
axonal loss 
Nerve biopsy 
2000: mild axonal 
loss, CK mildly 
elevated 
F1-3 TK-DE 17/F 16 Pain in her legs 
Gait only 
mildly 
impaired 
+ + +++ + - Mildly impaired TCC 
 
Normal 
NCV, 
Normal 
MAP-
amplitudes, 
Normal 
needle EMG 
CK normal 
F-BRA21325 BR 21/F 17 Walking difficulties Use of walker Severe ++ +++ + - Mental retardation 
TCC, 
PWM Normal  
F-BRA21326 BR 18/M 15 Walking difficulties 
Moderately 
impaired Moderate ++ +++ + - Mental retardation TCC Normal  
F14[CAL] IT 29/F 17 
Hypostenia, 
Difficulties 
in walking 
Severe 
Severe, 
unable to 
walk unaided 
+++ +++ + + Mental deterioration TCC, PWM 
Axonal 
Neuropathy  
F-BRA21215 BR 27/F 15 Gait abnormalities 
Wheelchair at 
24 yrs Severe + +++ MUTE - Mental retardation TCC Normal Dysarthria 
F-BRA21216 BR 21/F 17 Gait abnormalities Moderate ++ + +++ + - Mental retardation TCC ND Pes cavus 
F35[TER] IT 46 15 Spasticity Wheelchair at 23 yrs Severe + +++ + + Mental retardation TCC Neurogenic 
Severe 
psychosis, 
Allucinations 
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Patient ID code Origin (ISO cod) 
Age at 
examin
ation 
(years)/
sex 
Age at onset 
(years) 
Symptom at 
onset Severity 
LL 
spasticity/ 
weakness 
LL 
reflexes
UL 
reflexes 
Ext 
plantar 
Muscle 
wasting 
Mental Retardation/ 
Cognitive decline MRI EMG Other 
F-BRA12162 BR 24/M 8 
Deterioration 
in school 
performance 
Deterioration, 
now severely 
disabled 
Standing 
with support, 
no walking 
+++ +++ + - Mental retardation TCC ND  
F-BRA12163 BR 22/F 10 Walking difficulties 
Moderately 
impaired +++ ++ +++ + - Mental retardation ND ND  
F-BRA19070 BR 32/M 16 Spasticity Wheelchair at 27 yrs Severe - +++ + - Mental retardation TCC Normal  
F-BRA19069 BR 33/F 22 Stiff legs Cane at 32 Moderate - +++ + - Mental retardation TCC ND  
F-BRA19271 BR 27/F 23 Gait abnormalities Cane at 26 Moderate - +++ + - Mental retardation ND ND  
F17[SP] IT 29/M 6 Mild learning disabilities Mild Moderate +++ +++ + - 
Mental retardation/ 
Progressive cognitive 
deterioration 
TCC, 
PWM Normal Urinary urgency 
FB-1 IT 28/F 17 Feet deformities and stiff legs Severe 
Moderate/ 
Mild + - ++ + 
Mental retardation/ 
Progressive cognitive 
deterioration 
TCC, 
Cerebellar 
atrophy, 
Cortical 
atrophy 
Axonal 
Neuropathy 
Dysarthria, 
Severe pes cavus 
FB-2 IT 24/F 19 Falls Severe Moderate/ Mild + - ++ - 
Mental retardation/ 
Progressive cognitive 
deterioration 
TCC Axonal Neuropathy  
DKD-H82 IT 30 13 Stiffness while walking Severe 
Marked/severe
unable to 
walk 
+++ +++ + + Mental deterioration (2007 severe) 
Striking 
TCC, 
PWC 
Neurogenic 
changes  
DKD-H83 IT 26 17 
Hand tremor and 
difficulties in 
walking 
Moderate 
Marked 
walking 
difficulties 
+++ ++ + + Mental deterioration ibidem Neurogenic changes 
Slight 
adiadokinesia at 
finger to nose test 
F34[GARG] IT 29/F 22 Spasticity Mild Moderate - ++ + - - PWM Normal  
F9-1 BR 22/M 14 Gait disturbances Severe Severe/ Moderate + ++ ++ - Mild decline TCC Normal 
Slow eeg, 
Dysathria 
F9-2 BR 20/M 12 Pain in LL, Gait disturbances Severe 
Severe/ 
Moderate ++ ++ ++ - Mild decline TCC ND 
Pes cavus, 
Tremor upper 
limbs 
F33[COL] IT 27/F 15 Learning slow Mild Moderate + ++ + - Cognitive delay TCC, PWM Neurogenic Dysarthria 
F16[BRA] BR 23/F 17 Stiff legs Mild ++ + +++ + - Mental deterioration 
 
TCC, 
PWM 
Normal Dysarthria 
SP-H28 IT 20/F 15 Learning difficulties Moderate +++ ++ +++ + 
+ 
(distal) Mild decline 
TCC, 
PWM Normal 
Pes varus, 
Fragmented 
smooth pursuit 
SP-H29 IT 13/M 12 Walking difficulties Moderate ++ + - + - - PWM 
Axonal 
Neuropathy 
 
 
 
Pes varus, 
Fragmented 
smooth pursuit 
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Patient ID code Origin (ISO cod) 
Age at 
examin
ation 
(years)/
sex 
Age at onset 
(years) 
Symptom at 
onset Severity 
LL 
spasticity/ 
weakness 
LL 
reflexes
UL 
reflexes 
Ext 
plantar 
Muscle 
wasting 
Mental Retardation/ 
Cognitive decline MRI EMG Other 
F-NL02 NL 15 5 Deterioration of gait 
Moderate, 
at 15yrs still 
able to walk 
Moderate LL 
spasticity ++ +++ ++ - - 
Mildly 
increased 
signal of 
periventric
ular and 
deep 
cerebral 
WM, 
“Flames” 
at the 
frontal 
horns, 
Mild 
cerebral 
atrophy, 
Thin 
anterior 
CC 
Normal Mild Dysarthria  
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DISCUSSION 
In a large cohort of 31 families with HSP-TCC and in 20 sporadic cases we identified SPG11 disease alleles in 
25/51 index patients (49%). Broadening the spectrum of mutations in spatacsin, we identified 32 variations, of 
which 22 are novel, distributed all over the gene. Eleven nonsense mutations, eight small deletions, six small 
insertions, one small duplication and three mutations with effects on splicing were identified. Moreover, we detected 
one in/del and one large scale deletion sized about 9.0 Kb. The causative nature of the missense p.F1349I variant 
remains to be proved because single heterozygous deletions can have escaped detection in the carrier patient. 
Nonetheless, the p.F1349I, which affects a conserved amino acid and was associated with a truncated allele in trans, 
was absent in 300 control chromosomes. Moreover, this mutation is predicted to be intolerant (PolyPhen — 
www.genetics.bwh.harvard.edu/pph/ — and SIFT www.blocks.fhcrc.org/sift/SIFT.html) and could lead to loss of 
function of the protein. 
 Together with the already reported changes (Stevanin, et al. 2007; Del Bo et al. 2007; Hehr et al. 2007; Stevanin, 
et al. 2008; Boukhris et al. 2008a; Paisan-Ruiz et al. 2008; Zhang et al.2008; Lee et al. 2008; Erichsen et al. 2008), 
disease-associated mutations in SPG11 are now 67 and almost invariably alter the correct formation of a complete 
protein product in all except one case. If formed, the protein would be rapidly degraded or significantly shortened. 
Consequently, no significant domain-related clinical differences could be observed. As an example, the 
c.529_533del5 mutation lies in the first transmembrane domain whereas the c.3741_3742insA in the third 
transmembrane domain and the large deletion removes the Myb domain. These mutations presented with 
comparable age at onset, disease severity and progressive neurological impairment. The practical consequence of the 
large number of different mutations identified, in terms of the diagnosis of ARHSP-TCC, is that a quick, DNA-
based test seems unfeasible. We can speculate that a protein-based diagnostic assay of the type being developed in 
other forms of spinocerebellar degenerations [i.e., ALS2 (Eymard-Pierre et al. 2006), ataxia-telangectasia syndrome 
(Sutton at al. 2004) or ataxia with oculomotor apraxia type 1 (Ferrarini et al. 2007)] will be more effective. 
Our study enlarges the ethnic origin of SPG11 patients. Like in previous studies (Hehr et al. 2007; Stevanin et al. 
2008a), no population-related mutation seems to emerge in both Italian and Brazilian cases and frequent compound 
heterozygosity is observed which in turn might imply higher than expected carrier frequencies. Even within 
apparently homogeneous populations, a molecular diagnosis cannot be achieved without full gene sequencing. For 
example, in a total of 29 Italian index cases with compatible phenotypes (15 familial and 14 apparently sporadic 
patients), we detected 12 subjects — half of whom had no positive family history — harboring pathogenic variants 
in SPG11 (41%) and 21 different mutations broadly distributed along the coding exons. A similar ample allelic 
heterogeneity has been reported in Tunisian (Boukhris et al. 2008a), Pakistani (Paisan-Ruiz et al. 2008) and Turkish 
families (Hehr et al 2007). Interestingly, few mutations seem to be recurrent in patients’ population originating from 
the Mediterranean basin, indicating founder effects with subsequent migrations. The haplotypes segregating with the 
c.529_533del5 SPG11 mutation are particularly well conserved in the Brazilian and Portuguese cases, but the 
telomeric and centromeric portions of the haplotype segregating with the c.6100C>T mutation in patients from 
North Africa and Brazil are more divergent and might indicate a more ancient mutational event. However, a 
mutational hot spot cannot be excluded. Additional mutated families are required to date these events.  
When clinical features are driving molecular testing, roughly one case in two of familial complicated spastic 
paraplegia harbors SPG11 mutations (Table 4). Although we (Stevanin et al. 2007; Stevanin et al. 2008a; Boukhris 
et al. 2008a, and this study) and others (Hehr et al. 2007; Paisan-Ruiz et al. 2008) have at times noticed that 
intrafamilial differences are possible, and similar mutations not necessarily lead to similar onset and disease course 
(Table 3), SPG11 patients usually develop a progressive motor and cognitive deterioration from school years, but 
earlier learning problems and attention deficits are likely to occur. Combining evidence from this study and our 
previous reports (Stevanin et al. 2007; Stevanin et al. 2008a) it is clear that the presence of motor deterioration with 
signs of pyramidal dysfunction of the legs in young students who perform badly in junior-high school appears 
sufficient to propose a molecular testing after appropriate clinical and imaging evaluation. Practically all SPG11 
mutations are associated with a widely similar disease course with frank spastic paraplegia manifesting within the 
second-third decade of life. At the same time, cognitive deterioration worsens and produces in late disease stages 
frank dementia. The lower rate of progression observed in this study, when compared to previous analyses (Stevanin 
et al. 2008a), might relate to ethnic differences among patients or to a different clinical setting, being mostly 
pediatric in our study and more related to adult neurology centers in the previous one. 
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Table 4. Frequency of SPG11 mutations according to the clinical categories outlined in the Methods. 
Phenotypes Group I: HSP +  
MR + TCC 
Group II: HSP + TCC Group III: HSP + MR,  
no TCC 
Group IV: Apparently  
pure HSP 
Sum 
Number of  
index cases  
Familial 
 
 
20 
8 
 
 
4 
10 
 
 
4 
2 
 
 
3 
0 
 
 
31 
20 Sporadic 
Mutation  
detected  
Familial 
 
 
14/20§ (70%) 
§Refer to index cases in the families. 
Sporadic 8/8 (100%) 
 
 
1/4§ (25%) 
1/10 (10%) 
 
 
0/4 
0/2 
 
 
1/3 (33%) 
0 
 
 
16/31 (52%) 
9/20 (45%) 
 
Neuroimaging appears even more helpful in deciding on performing genetic analyses. Thin rostral corpus 
callosum with a “beaked” shape and mostly sparing the splenium, frequently associated with "flames" at the frontal 
horns involving periventricular and deep cerebral white matter, with or without mild cerebral atrophy, appear the 
distinctive neuroradiological features of this disorder. In advanced disease stages, atrophy of higher cortical regions 
such as the prefrontal cortex matches thinning of the anterior corpus callosum (Figure 3). In a small set of 
individuals presenting without TCC, mutations in SPG11 are found (8% in this study; 4.5% in Stevanin et al. 2008a) 
after a disease duration of less than 5 years. In such cases, however, either the presence of a sib with a full syndrome 
(clinical and neuroradiological) or evidence of learning disabilities and white matter lesions raise the clinical 
suspicion and we cannot exclude that follow-up MRI might show a “curved” shaped, thinner anterior corpus 
callosum. 
 
 
Figure 3. Axial and sagittal brain MRI images after a 7-year follow up in patient SP-H28 harboring the 
heterozygous p.F1752SfsX1837 and p.C1996LfsX1999 mutations in SPG11 showed worsening of TCC, “flames” at 
ventricular horns, and progression of cortical atrophy.
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When clinical and neuroradiological features are combined, they also remain a useful criterion for deciding to 
screen isolated patients. In our cohort, 9/20 of cases (45%) with complicated HSP without a positive family history 
harbored mutations in SPG11. Eight patients had a combination of HSP+TCC and cognitive impairment (Table 4). 
This higher than expected positive mutation rate is different from what has been observed by others (1/25, 4%) 
(Paisan-Ruiz et al. 2008) but might depend on the use of more stringent selection criteria or might relate to different 
patients’ ethnicities. In general, however, it is hard to speculate on the rate of SPG11 mutations when patients under 
screening have less canonical phenotypes, such as HSP + mental retardation without TCC or pure spastic paraplegia 
with onset in early adulthood and no family history because we did not test enough patients meeting these criteria. 
Analyses in this latter group of patients, by far the most frequent in the clinical practice, require more cost-effective 
modalities of molecular screening after a more complete clinical examination and a dedicated SPG11 testing. 
About half of patients, both sporadic and familial, did not show mutation in SPG11 notwithstanding our in depth 
mutation screening. The clinical presentation and the MRI features in such cases did not grossly differ from patients 
having both alleles mutated. These findings reinforce previous notions on genetic heterogeneity in ARHSP-TCC 
(Casali et al. 2004; Boukhris et al. 2008a). Although the presence of non-conventional variants remains possible, 
mutations in other genes are also to be expected. For instance, it has been shown that a subgroup of ARHSP-TCC 
with clinical features highly similar to SPG11 cases (Elleuch et al.2007) are instead linked to the SPG15 locus on 
chromosome 14q (about one in four in Boukhris et al. 2008a; Boukhris et al. 2008b) or mutated in the corresponding 
gene (Hanein et al. 2008). The future identification of other HSP-TCC related genes will permit better correlations 
with neuroimaging and clinical phenotype. 
In summary, SPG11 mutations appear the most frequent genetic determinant of autosomal recessive HSP 
worldwide with cases described on European, Asian and North-African genetic background. At least in Italy, SPG11 
seems to account equally for sporadic and familial cases and it currently denotes the most common etiology in 
ARHSP, with or without TCC, mirroring what SPG4 represents for the autosomal dominant forms. Our results 
suggest that SPG11 should be tested in patients, even with no family history, if progressive motor degeneration and 
early onset mental decline are associated with distinctive brain MRI since onset or after a few years of disease 
duration. 
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Supp. Table S1. Oligonucleotide primers and annealing temperatures (T-°C) used to amplify the 5’- and 
3’-untranslated regions (UTR) of the SPG11 gene and two novel intragenic dinucleotide markers. 
 
Region flanking 
SPG11 FORWARD SEQUENCE (5'-3') REVERSE SEQUENCE (5'-3') T°C 
5'UTR-1 CAGGCGTCAAAGAAAGCACT TAGCAAAGCCACATCTGCC 60° 
5'UTR-2 TAAGCTTAGCTGGGGCTGTG CCTTGCCAACATAGGGAGAC 60° 
5'UTR-3 AGGATAGCCTTCATTACAGGTTT TTCTGAGGACAGAGATGACCA 60° 
3'UTR TGGATGAACAATCATCTAAAATCAA TCATAAAACTTGTGTTCGTATGCC 60° 
    
Intragenic 
SPG11 markers 
   
chr15:42720928 GAATACATCCACCACACAAAC GTGCTGGCAAGAACATCAAG 60° 
chr15:42800751 CATATTATACCACACTTACC TTTGGAAAGTCAAGGTGAGC 60° 
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Supp. Table S2. Oligonucleotide primers, annealing temperature (Ta-°C PCR), anticipated product size in 
base pairs (bp) and DHPLC conditions (T-°C DHPLC) used to analyze the 40 exons of the SPG11 gene. 
 
Exon bp Ta-°C PCR 5'- 3' Primers Forward/Reverse T-°C 
DHPLC 
1 308 60 agtcaggttccggcgaaagt /ccaactctccctcagcactt 54.8 
2 323 62 accaggtcaactaaactgttctct / tatgctgaaagaccacctgtaga 55.3 
3 305 58 ccagttgtaaaattgtgacc / tcaatcaacacttctaccac  55.1 
4 320 62 gttaggcatacttacaaaactggc / cgaggatatttttaacctcttatca 54.8 - 52.8 
5 330 60 caggagcagtagtaacacaa / aaagggtacagcgtcagcat 54.9 
6 450 58 ctgtgacaggtgttaagtta / atctaatacaagacagtctc 54 
7 275 58 tagtactgaagtattgagta / ttaagtaatgttcttgggca 50.6 
8 450 60 cttgccccagattgcataat / tccaaaaagtacgtaaaatccca 54.1 
9 342 62 gcaggtaataagcctgcagaa/cccccttcctagctgctatt 54.1 
10 331 62 cacacacacaaattggcaca / aacctttgccaaacattctga 54.1 
11 293 57 gttacataaatgtataatccctg / cattttaagactttatggattac 54.6 
12 210 62 tgttcaaaatagttccattacaaaa / tttcttccaaggttttcttcca 52.5 
13 289 62 tttgcaaaagtgcttgatttt / tgcaggctcagttccacata 51.5 
14 246 62 ggaatgatgcctttttctcc / tctcacacttgccttctgga 55.8 
15 345 60 cacagcgagatcctgtctca / cctcactgtaagatgatgccc 55-58 
16 309 62 tgtgggcatgatttggtcta / acctgctcaaggacaaatgc 55.2 
17 239 62 aatcatcgcctgagcaaaat / ccagtgactgatccaaagca 53.9 
18 324 58 ccctcttaaggagaaaaacac / cagccttatcctctgctctt 53-50 
19 299 60 gctaatcttgtttcacaagg / cctggctgaactctgataga 55 
20 311 62 tggaaaaggggagcagacta / tgcgaactatttttcctttgg 52.3 
21 303 58 ttccatgtgcaaatctgaaatta / tcccaaagtgctgggattac 58 
22 383 62 gaggaggccacaaatcacat / gccttagacctcgtcacacc 55.8 
23 356 62 tgctcaggttttgactttttctc / tttcactgatggcaagatgc 53.1 
24 267 60 accacccccacctctaattc / ctacacaacagaaagaatgc 57.1 
25 361 60 ccagctgaaactgaaagttgg / ctgggtacttacttcaggct 56.6 
26 293 60 tgtacatttgccaggtaatcca / cttaagctctggaaagaagtg 56 
27 330 62 cactgtgccctgccttatta / tgtgcctgagtaaccgagtg 53.6 
28 329 62 tcccagatttggaggttttg / tgcattttaatttcctaactaccc 53.5 
29 330 56 gctgtagtggcattttattg / cctgggtgacagagcaagac 56 
30a 323 62 gaggtgggaggatctcttg / gatgtgttcagagcagccaa 58-55 
30b 304 62 taagctggaggagctggaga / ttgttgtccccttaacttgg 58-55 
31 318 62 cagggagcttcaagcagaga / tgacttggcaatgtccaaaa 56.9 
32 323 60 cctggcttctaaaagtggcc / aagcacaacatccaaatcctt 58.8 
33 349 62 agctgcagagctccataagc / taggcatccagagcaggaac 57.6 
34 336 62 gaggttgacagtgggcagcca / gcccagccaactctcaagta 56.9 
35 312 62 ggcatctgaaagcaaccact / ccctccattttcccaagagt 54 
36 376 62 caacaggaaagcacacatgc / gtgtggctgtgacctcactc 52 
37 313 62 aacatggctgggatgtttct / ttcctggttggcctatgatg 57.6 
38 315 62 ggggtgaataccgttgtgag / acctctgggttccatgagtg 56.9 
39 380 62 aatgccaaacacacacctga / ctcaaagcagaggcaaggag 53.2 
40a 390 62 agactgctcctctgcactcc / ccgggattgttcaactttagc 54.4 
40b 321 58 cagtatcttaacctgtacat / ccgggattgttcaactttagc 54.2 
 
